JPRN-UMIN000001599已完成1 期
CHP-MAGE-A4 vaccine study for MAGE-A4-expressing cancer - CHP-MAGE-A4 vaccine study
CHP-MAGE-A4 cancer vaccine study at Mie University0 个研究点目标入组 6 人开始时间: 2008年12月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.HIV-positives. 2.Double cancers. 3.Autoimmune disease. 4.History of serious hypersensitivity. 5.Active CNS metastasis. 6.Lasting less than four weeks from the previous chemotherapy, systemic corticostoroid, immuno-suppressive or -stimulating agents, radiotherapy, or surgery to primary tumors 7.Pregnant or lactating. 8.Inappropriate for study entry judged by an attending physician.
研究者
相似试验
已完成
1 期
CHP-MAGE-A4 cancer vaccine study for refractory MAGE-A4-expressing cancerMAGE-A4-expressing refractory cancer patients (non origin-limited) or patients who refuse standard therapyJPRN-UMIN000002153The Tazuke Kofukai Medical Research Institute6
已完成
1 期
CHP-MAGE-A4 vaccine study for patients with advanced lung cancerMAGE-A4-expressing therapy-resistant lung cancerJPRN-UMIN000001680CHP-MAGE-A4 cancer vaccine study at University of Occupational and Environmental Health, Japan6
已完成
1 期
A phase I study of cancer vaccine with CHP-MAGE-A4 in patients with advanced cancers expressing MAGE-A4 antigeAdvanced esophageal cancer, stomach cancer, non-small cell lung cancer (NSCLC), colon cancer.JPRN-UMIN000003188Department of Surgery Osaka University Graduate School of Medicine20
已完成
不适用
MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene"Therapy-resistant esophageal cancerJPRN-UMIN000006507Mie University Graduate School of Medicine18
已完成
4 期
to evaluate the Immunogenicity and Safety of Typbar-TCV® in AdultsCTRI/2019/10/021823Bharat Biotech International Ltd300